BMYBristol-Myers SquibbRunning, no new patients
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Leukemia, Myeloid, Acute
13Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2025, none posted yet
Counts until it's fixed
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score13
Score over time
- Stage
- Phase 2
- Patients
- 34 (final count)
- Started
- Aug 19, 2022
- Main results expected
- Oct 31, 2025
- Fully finished
- Oct 31, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Relapse-free survival (RFS)
Measured over: Up to 30 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-10-31, no fading
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05413018 · record last updated 2026-04-28 · checked 2026-11-09 15:47 UTC